Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.07.2021 | Case report

Ipilimumab/nivolumab

Oesophagitis and pneumonitis: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Alhalabi O, et al. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. International Journal of Cancer 149: 387-393, No. 2, 15 Jul 2021. Available from: URL: http://doi.org/10.1002/ijc.33560 Alhalabi O, et al. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. International Journal of Cancer 149: 387-393, No. 2, 15 Jul 2021. Available from: URL: http://​doi.​org/​10.​1002/​ijc.​33560
Metadaten
Titel
Ipilimumab/nivolumab
Oesophagitis and pneumonitis: 3 case reports
Publikationsdatum
01.07.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-99922-4

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Atorvastatin

Case report

Hyaluronic-acid

Case report

Antineoplastics

Case report

Asparaginase